Repeated Methamphetamine-treatment Alters Brain Sigma Receptors

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 1993 Jan 12

PMID 8422906

Citations 23

Authors

Y Itzhak

Affiliations

Soon will be listed here.

Abstract

The present study was undertaken to examine whether repeated exposure of rats to the psychostimulant drug, methamphetamine, induces changes in sigma receptor binding. A significant up-regulation (130-145% of control Bmax) of sigma receptors, labeled with [3H](+)pentazocine, was observed in the substantia nigra, frontal cortex and cerebellum of rats treated with methamphetamine (4.0 mg/kg per day; 10 days). These findings suggest that methamphetamine-induced psychosis may be associated with the up-regulation of sigma receptors in critical brain regions.

Citing Articles

Comprehensive Analysis of Age- and Sex-Related Expression of the Chaperone Protein Sigma-1R in the Mouse Brain.

Tarmoun K, Lachance V, Le Corvec V, Belanger S, Beaucaire G, Kourrich S Brain Sci. 2024; 14(9).

PMID: 39335377 PMC: 11430507. DOI: 10.3390/brainsci14090881.

Methamphetamine Blocks Adenosine A Receptor Activation via Sigma 1 and Cannabinoid CB Receptors.

Casanovas M, Reyes-Resina I, Lillo A, Lillo J, Lopez-Arnau R, Camarasa J Int J Mol Sci. 2021; 22(5).

PMID: 33803075 PMC: 7963146. DOI: 10.3390/ijms22052743.

Cannabidiol attenuates methamphetamine-induced conditioned place preference via the Sigma1R/AKT/GSK-3β/CREB signaling pathway in rats.

Yang G, Liu L, Zhang R, Li J, Leung C, Huang J Toxicol Res (Camb). 2020; 9(3):202-211.

PMID: 32670551 PMC: 7329178. DOI: 10.1093/toxres/tfaa021.

The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Sambo D, Lebowitz J, Khoshbouei H Pharmacol Ther. 2018; 186:152-167.

PMID: 29360540 PMC: 5962385. DOI: 10.1016/j.pharmthera.2018.01.009.

Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway.

Hedges D, Obray J, Yorgason J, Jang E, Weerasekara V, Uys J Neuropsychopharmacology. 2017; 43(6):1405-1414.

PMID: 29185481 PMC: 5916361. DOI: 10.1038/npp.2017.291.